Diuretics in Hypertension Management: Mechanistic Insights and Clinical Implications for Modern Therapeutics

Abstract

Diuretics remain a cornerstone in the management of hypertension and various fluid overload conditions, including heart failure, nephrotic syndrome, and liver cirrhosis. This review examines their pharmacological mechanisms, therapeutic applications, and evolving clinical positioning across a range of disease. Over the decades, hypertension guidelines have shifted in their preference for diuretics versus newer antihypertensive agents, often driven by concerns about metabolic side effects and evidence from landmark clinical trials. Despite these fluctuations, thiazide diuretics—especially chlorthalidone and indapamide—have consistently demonstrated strong efficacy in reducing cardiovascular morbidity and mortality, provided that optimal dosing is used to minimize adverse metabolic effects such as hypokalemia, dyslipidemia, and impaired glucose tolerance. The utility of diuretics extends to key patient populations, including those with type 2 diabetes mellitus, a history of stroke or transient ischemic attack, salt-sensitive hypertension, and low-renin states. In these contexts, diuretics often play a central role either as monotherapy or as part of rational combination regimens alongside renin-angiotensin system inhibitors or calcium channel blockers. While diuretic resistance, electrolyte disturbances, and individual variability pose therapeutic challenges, these can often be managed through careful patient selection and monitoring. This review reaffirms the integral role of diuretics in modern antihypertensive strategies and advocates for their personalized application based on patient-specific risk profiles and comorbidities.

Keywords

Introduction

A diuretic is any substance that promotes diuresis, the increased production of urine. All diuretics increase the excretion of water from bodies, although each class does so in a different way. A closer look at their therapeutic roles highlights their importance in managing complex conditions involving fluid imbalance and cardiovascular risk. Their diverse mechanisms and wide range of clinical applications make diuretics a fundamental component of modern pharmacotherapy.  Diuretics are a mainstay of therapy for a wide variety of diseases ranging from hypertension to nephrotic syndrome. Diuretics are the drugs of choice for congestive heart failure, preferably combined with Angiotensin Converting Enzyme Inhibitors. Thiazide diuretics are the preferred drugs in most hypertensive patients, including diabetics, either alone or combined with drugs from other classes. Of all drugs for HF treatment, diuretics are therapeutically superior in their efficacy in relieving clinical symptoms and signs. They are recommended in the presence of congestion until the achievement of a euvolemic state and subsequently to prevent the recurrence of fluid retention. Generalized oedema can develop in nephrotic syndrome, chronic kidney disease, heart failure, and liver cirrhosis. Usually, patients with oedema respond to dietary sodium restriction in combination with a loop diuretic. Understanding the place of diuretics in the treatment of hypertension is complicated by the fact that in many countries, they are more commonly prescribed in combination therapies. The emphasis of guidelines on combination treatments and single-pill combinations continues to increase.

Variation in Diuretic Effects

The diuretics currently available differ widely concerning the maximum diuresis that they can produce. The peak diuresis from mercurial diuretics in an individual pretreated with acidifying salts may amount to some 15 to 20% of the glomerular filtrate. The maximum effect from drugs of the thiazide group is not often more than half that amount and with the aldosterone antagonists, carbonic anhydrase inhibitors, and other lesser diuretics, the maximum effect is again much smaller. With ethacrynic acid and with frusemide the peak effects are as great as 30% or more of the glomerular filtrate. These figures, of course, represent what under most favourable circumstances may be observed at the transient peak. This peak is transient not only because the maximum drug effect may be of limited duration, but because diuresis of the larger magnitude alluded to cannot persist for very long before the individual runs out of fluid.  In an average-sized individual with a normal rate of glomerular filtration, 20% of the glomerular filtrate is about 35 Liters in 24 hours. In fact, in clinical use, the effect to be expected with any of these agents is considerably smaller than the maximum. For the effect of a diuretic over 24 hours to average as much as half of the maximum is unusual, indeed. Nevertheless, the diuresis to be expected is related in a general way to these potencies, and this must be kept in mind, as these new and powerful diuretics become available, as an indication of the massive diuresis that may sometimes be induced by their vigorous application. Because diuresis is inherently self-limited, however, it is perhaps more important than the extent of dehydration-that is, loss of extracellular fluid capacity which diuresis ceases will, in general, be proportional to the potency of the diuretic and, with the most potent, a patient may be carried well below his normal dry weight before a new balance is struck.

Reaffirming the place of diuretics in hypertension and comorbidities

1. Hypertension

When diuretics were introduced in the 1960s, they were mainly used as an adjunct therapy to more powerful drugs such as the adrenergic agents or hydralazine, used in the treatment of moderate or severe hypertension. By the seventies, beta-blockers had been accepted and therapy extended to milder grades of hypertension, using 'step therapy', a regimen in which treatment was initiated with a diuretic, with the addition, if necessary, of a beta blocker and then of a vasodilator, usually hydralazine. The availability of new classes of blood pressure-lowering drugs – the ACEI, the CCB, and the alpha-blockers – coincided with the publications of the landmark meta-analysis by Collins et al. which revealed that the expected reductions in stroke were realized but that the reduction in myocardial infarction was disappointing, being much less than predicted by the major observational studies. Many thought that diuretics, with their well-known metabolic side-effects such as hypokalaemia, dyslipidaemia, and glucose intolerance might be responsible. Therefore, newer agents gained favour in the eighties, step therapy was discarded and the age of monotherapy was ushered in, with widespread belief that single-drug therapy would suffice, with attractive simplicity and efficacy. Three major trials in the early 1990s showed that, despite metabolic side effects, diuretics were highly effective in preventing stroke and coronary heart disease in older adults. This evidence, coupled with the lack of similar outcomes for ACE inhibitors and calcium channel blockers, led to a renewed acceptance of diuretics and beta-blockers as first-line treatments. By the mid-1990s, major guidelines endorsed diuretics—especially for the elderly—with American guidelines even recommending them as the preferred starting therapy, though WHO-ISH favored a more individualized approach. In the 21st century, treatment has expanded to include high-risk normotensive patients, and combination therapy has become the standard. While diuretics remain a first-line option, their exact role varies across guidelines. These shifts underscore diuretics' lasting value, especially in older and high-risk patients, even as hypertension management grows more tailored and combination-focused.

Guidelines throughout the world list diuretics as one of the first-line treatments for patients with essential hypertension. This choice is based on the observation that a wide range of patients can benefit from diuretics, which counter the extracellular volume expansion and the salt retention associated with hypertension and reduce morbidity and mortality. For most patients, the risk of a clinically meaningful change in laboratory parameters is rather low, whereas the clinical benefits of diuretics are high. There was disagreement among the most recent major guidelines, with the American (JNC7) and International (WHO-ISH) guidelines recommending initiation of therapy with diuretics, whereas the Europeans (ESH/ESC) and Canadians recommend that clinicians should tailor the choice among first-line classes (which include diuretics) according to the clinical profile of the individual patient. The result of the massive ALLHAT study tipped American opinion towards diuretics, as reflected in JNC 7. In contrast, the results of ANBP2 and more recently of the very large ASCOT-BPLA trial favour initiation with the 'newer agents', angiotensin-converting enzyme inhibitors (ACEI) and calcium channel blockers (CCB). Indeed, the authors of the ASCOT-BPLA trial, which compared a regimen using CCB and ACEI with one using beta blockers and diuretics, believe that the latter two classes should be relegated to second-line status. There is often confusion when discussing blood pressure treatments. A common issue is the tendency to focus too much on the first drug used in combination therapy. This can lead to the mistaken belief that the outcomes are mainly due to that single drug. In reality, the other drugs in the regimen also contribute to the results. Some guidelines from the 1990s, such as JNC 5 and JNC 6, may have made this error by giving too much credit to diuretics, without fully considering the role of the other medications used in the treatment.

Thiazide diuretics were the first efficient antihypertensive drugs that significantly reduced cardiovascular morbidity and mortality in placebo-controlled clinical studies. Although these drugs today still are considered a fundamental therapeutic tool for the treatment of hypertensive patients, the following considerations should be taken into account. Although there are some indications that chlorthalidone can offer additional advantages as compared with other compounds, a recent meta-analysis of placebo-controlled trials suggested that the beneficial effects of thiazide diuretics could be a class effect.  Thiazide diuretics must be used at appropriate and/or optimal doses to achieve the optimal antihypertensive effect with the smallest occurrence of side effects, including alterations in glucose and lipid profiles and hypokalaemia. Moreover, because thiazide diuretics can increase the incidence of new-onset diabetes, especially when combined with blockers, caution is advised in using these drugs above all in patients who are at high risk for developing diabetes, in whom thiazide diuretics should be used at the lowest active dose and possibly in combination with drugs that block the renin-angiotensin system.  Finally, the current debate on whether thiazide diuretics are the first-choice drug for most patients with uncomplicated hypertension, as stated in the Seventh Joint National Committee Report, or are included in the major classes of antihypertensive agents that are suitable for initiation and maintenance of therapy, as reported in the European Society of Hypertension–European Society of Cardiology Guidelines, derives from different interpretations of controlled clinical trial data on drug class comparison and of cost-benefit analyses. However, considering that the benefit of antihypertensive drugs seems to be due principally to BP lowering per se without definitive evidence of the superiority of a particular drug class and that there is no cost-benefit analysis showing the superiority of thiazide diuretics, it is believed that these drugs should not be considered as the only first-choice drug but included among first-choice drugs.

b. Type 2 diabetes mellitus

In hypertensive patients with diabetes mellitus, particularly those with kidney disease, RAS inhibitors are a first-line treatment. However, as hypertensive patients with diabetes mellitus are prone to fluid retention and are at significant risk of developing heart failure or renal impairment, such patients are also likely to benefit from the volume control and/or natriuresis provided by diuretics, despite the potential effect of some diuretics on metabolic parameters. This dichotomy is reflected in guidelines: American Diabetes Association guidelines and Hypertension Canada guidelines support equally the prescription of diuretics and RAS inhibitors, but give preference to RAS inhibitors in the presence of proteinuria or microalbuminuria. The most recent European Society of Cardiology and European Society of Hypertension (ESC/ESH) guidelines have addressed this issue by recommending the initiation of treatment with a combination of a RAS inhibitor and a diuretic (or a CCB).

c. History of stroke

Several recent guidelines underscore the importance of treating patients with a history of stroke or transient ischemic attack with a diuretic and possibly with a diuretic/ACE inhibitor combination. Latin American Society of Hypertension guidelines specifically recommend indapamide sustained release, possibly in combination with an ACE inhibitor, as a first-line treatment.

d. Salt-sensitive and low-renin hypertension

Patients with salt-sensitive hypertension and/or low-renin hypertension have characteristics that lend themselves well to treatment with a diuretic. In most cases, low levels of renin are an indication that the RAS is suppressed because of volume overload and sodium retention. In such patients, as well as in salt-sensitive patients, treatment with diuretics, which reduce volume and increase sodium excretion, would be expected to be efficacious, whereas treatment with RAS inhibitors would be expected to suppress the RAS further. In fact, in the few clinical trials that have looked at patients with low-plasma renin activity and/or salt sensitivity, effective blood pressure-lowering strategies include HCTZ, chlorthalidone, indapamide, or spironolactone.

Potential and Limitations of Diuretic Therapy

From these general considerations concerning diuretics and their effects, we may turn to a review of the potentialities and limitations of current diuretic therapy. The thiazides constitute the group of diuretics that are the most generally used.  Possibly chlorothiazide itself stands a little below the rest because of its relatively higher activity as a carbonic anhydrase inhibitor, which property could conceivably contribute to an undesirable increase in its tendency to produce potassium loss. Even in this case, however, the extent of carbonic anhydrase inhibition is unlikely to be sufficient to be a factor as the drug is generally used. With the others, this problem disappears virtually completely. Various claims have been made that one or another of the drugs of this group produces less potassium loss than the others. There is good ground for extreme scepticism concerning this point. As indicated earlier, the induction of potassium loss is a nonspecific property of diuretics and of the circumstances under which they are used.  The thiazides also differ among themselves in the exact magnitude of the dose required to produce a particular effect. This, too, is a trivial matter. The ratio of toxic dose to effective dose is extremely high for all of these drugs so that a somewhat lesser potency on a weight basis is easily compensated for by an increase in dosage. The only consideration of importance is the effect observed when the dose is adequate to produce a maximum effect. In this respect the members of the group are identical.  Side effects other than those directly attributable to the diuretic action of this group have, on the whole, been minor. Some interference with urate excretion has been generally encountered, and the fact that similar effects have already been noted with ethacrynic acid and with frusemide suggests that this may be a general property of effective diuretics. This is not often of clinical consequence but should be watched for. The addition to the regimen of a uricosuric agent might be desirable in occasional instances. Disturbances in carbohydrate metabolism have also been found in patients receiving thiazides. No serious or irreversible consequences have been established, but the problem should be kept in mind.  Potassium depletion which we have already discussed is not an effect unique to this group of diuretics. Potassium supplements can be used, if necessary, but they should be adequate. An additional 8 or 10 mEq per day in an individual whose dietary intake is likely to be 60 or 70 mEq is not likely to make much difference. High-potassium foods are greatly preferred since gastric irritation from pure potassium salts is a common problem and since the danger of intestinal ulceration and stricture from the administration of enteric-coated potassium salts has become apparent. The use of potassium-diuretic combinations is, in my view, to be discouraged since the amounts of potassium in these are, on the whole, rather small and are unlikely to balance the requirements of any particular individual patient but give a false sense of security.

The aldosterone antagonists and triamterene, which, although not an aldosterone antagonist, have very similar effects, are, by themselves, rather weakly diuretic. While they may be valuable in an occasional relatively easily maintained patient, there may be reason to question whether such patients need diuretic therapy at all. The chief value of these agents is, in combination with other more effective diuretics, in reducing losses of potassium and correspondingly increasing sodium loss, particularly in the more diuretic-resistant patient. Some caution and frequent checks are, however, advisable since it is not difficult, at times, to induce an undesirable degree of potassium retention and hyperkalaemia.

CONCLUSION

Diuretics continue to play a fundamental role in the management of hypertension and associated comorbidities, including heart failure, chronic kidney disease, and cerebrovascular disease. Their broad utility, cost-effectiveness, and proven efficacy in reducing cardiovascular morbidity and mortality underscore their relevance in contemporary clinical practice. Among them, thiazide diuretics remain particularly effective as first-line or adjunctive agents, especially in salt-sensitive and low-renin hypertensive populations. Nonetheless, the clinical application of diuretics requires careful consideration of individual patient characteristics, particularly in those at increased risk for metabolic disturbances such as dyslipidemia, glucose intolerance, or hypokalemia. The current evidence supports their use within rational combination regimens, often alongside agents that mitigate potential adverse effects, such as renin-angiotensin system inhibitors. While the therapeutic landscape has evolved with the emergence of newer antihypertensive agents, diuretics retain their status as essential, evidence-based tools in achieving optimal blood pressure control and improving long-term clinical outcomes.

Future research should continue to refine patient selection, dosing strategies, and combination approaches to maximize benefit while minimizing harm, reaffirming the enduring value of diuretic therapy in cardiovascular medicine.

REFERENCES

1. Chithara PG, Dr.yogananda R, Dr.Bharathi DR., Prescription pattern of diuretics in a tertiary care hospital. Biomedical and pharmaceutical research, 8(3), 2019, 74-78
2. Williams B, ManciaG, SpieringW, AgabitiRoseiE, Azizi M,Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hyper tension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertense 2018; 36:1953–2041
3. Nachiya J, Parimalakrishnan S, Rao RM. Study on drug utilization pattern of antihypertensive medication on out-patients and inpatients in a tertiary care teaching hospital A cross-sectional study. African journal of pharmacy and pharmacology, 9(11), 2015, 383-396
4. McCoy IE, Chertow GM, Chang TI. Pattern of diuretic use in the intensive care unit., PLOS ONE, 14(5), 2019.
5. Arampatzis S, Funk GC, Leichtle AB, Fieldler GM, Schwarz C, Zimmermann H, Exadaktylos AK, Lindner G et al., Impact of diuretic therapy-associated electrocyte disorders present on admission to the emergency department A cross-sectional analysis. BMC Medicine, 11(83), 2013, 1741-2015
6. Chalmers J, Chapman N. Development of blood pressure lowering therapy: From trials to practice. In: Birkenhager W, Robertson J, Zanchetti A (eds). Handbook of Hypertension, Vol. 22: Hypertension in the twentieth century. Amsterdam: Elsevier, 2004; 504–25.
7. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38.
8. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74.
9. ROBSON, A. O., KERR, D. N. S., ASHCROFT, R., AND TEASDALE, G.: Diuretic response to frusemide. Lancet 2: 1085, 1964.
10. National Clinical Guideline Centre. Hypertension. The clinical management of primary hypertension in adults (NICE clinical guideline 127). London, United Kingdom. 2011.
11. Gabb GM, Mangoni AA, Anderson CS, Cowley D, Dowden JS, Golledge J, et al. Guideline for the diagnosis and management of hypertension in adults- 2016. Med J 2016; 205:85–89.
12. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al., Hypertension Canada. Hypertension Canada’s 2017 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol 2017; 33:557–576.
13.  Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (See comment). Hypertension 2003; 42: 1206–52.
14. European Society of Hypertension–European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003; 21: 1011–53.
15. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-con verting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
16. LinJJ, ChangHC, KuCT, ChenHY. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. Eur Rev Med Pharmacol Sci 2016; 20:2926–2934.
17. Niarchos AP, Weinstein DL, Laragh JH. Comparison of the effects of diuretic therapy and low sodium intake in isolated systolic hypertension. Am J Med 1984; 77:1061–1068.
18. Qi H, Liu Z, Cao H, Sun WP, Peng WJ, Liu B, et al. Comparative efficacy of antihypertensive agents in salt-sensitive hypertensive patients: a network meta-analysis. Am J Hypertens 2018; 31:835–846.
19. Kobalava ZD, Kotovskaya YV, Kravtsova OA. Plasma renin activity and potential of indapamide retard to improve control of hypertension. Kardiologiia 2015; 55:21–26.